Skip to main content
Top
Published in: Cancer Causes & Control 10/2006

01-12-2006 | Original Paper

Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020

Authors: Angela B. Mariotto, K. Robin Yabroff, Eric J. Feuer, Roberta De Angelis, Martin Brown

Published in: Cancer Causes & Control | Issue 10/2006

Login to get access

Abstract

Objective

This study provides projections of colorectal cancer prevalence by phases of care (initial, monitoring, and last year of life) to the year 2020 and describes the estimation method.

Methods

Cancer prevalence by phase of care was estimated from colorectal cancer incidence and survival from the Surveillance, Epidemiology, and End Results (SEER) Program data, population estimates and projections from the US Census Bureau, and all cause mortality data from the Human Mortality Life Tables. Assumptions of constant incidence and survival were used for projections from 2000 to 2020. Modeled and directly observed patient months by phase of care were compared for 1996 −1998 to provide validation of estimates.

Results

Prevalence of colorectal cancer is estimated to increase from 1,002,786 (0.36%) patients to 1,522,348 (0.46%) patients between 2000 and 2020. The estimated number of person-months in the initial and last year of life phases of care will increase 43%, while the monitoring phase of care will increase 54%. Modeled person-months by phase of care were consistent with directly observed measures of person months by phase of care in 1996–1998.

Conclusions

Under assumptions of current cancer control strategies we project that colorectal cancer prevalence will increase more rapidly than the US population, largely due to the aging of the US population. This suggests that considerable resources will be needed in the future for initial, continuing and last year of life treatment of colorectal cancer patients unless notable breakthroughs in primary prevention occur in the future years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Brown ML, Riley GF, Potosky AL, Etzioni RD (1999) Obtaining long-term disease specific costs of care: application to medicare enrollees diagnosed with colorectal cancer. Med Care 37(12):1249–1259PubMedCrossRef Brown ML, Riley GF, Potosky AL, Etzioni RD (1999) Obtaining long-term disease specific costs of care: application to medicare enrollees diagnosed with colorectal cancer. Med Care 37(12):1249–1259PubMedCrossRef
2.
go back to reference CDC. Cancer Survivorship – United States (1971–2001) MMWR 6-25-2004; 53(24):526–529 CDC. Cancer Survivorship – United States (1971–2001) MMWR 6-25-2004; 53(24):526–529
4.
go back to reference Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12(1):88–93PubMedCrossRef Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12(1):88–93PubMedCrossRef
5.
go back to reference Pickhardt PJ, Choi JR, Hwang I, et al. (2003) Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349(23):2191–2200PubMedCrossRef Pickhardt PJ, Choi JR, Hwang I, et al. (2003) Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349(23):2191–2200PubMedCrossRef
6.
go back to reference Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345PubMedCrossRef Cunningham D, Humblet Y, Siena S, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345PubMedCrossRef
7.
go back to reference Poynter JN, Gruber SB, Higgins PD, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184–2192PubMedCrossRef Poynter JN, Gruber SB, Higgins PD, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184–2192PubMedCrossRef
8.
go back to reference Gatta G, Capocaccia R, Berrino F, Ruzza MR, Contiero P (2004) The EUROPREVAL working group. Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Ann Oncol 15(7):1136–1142PubMedCrossRef Gatta G, Capocaccia R, Berrino F, Ruzza MR, Contiero P (2004) The EUROPREVAL working group. Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Ann Oncol 15(7):1136–1142PubMedCrossRef
9.
go back to reference Mariotto A, Warren JL, Knopf KB, Feuer EJ (2003) The prevalence of patients with colorectal carcinoma under care in the US. Cancer 98(6):1253–1261 Mariotto A, Warren JL, Knopf KB, Feuer EJ (2003) The prevalence of patients with colorectal carcinoma under care in the US. Cancer 98(6):1253–1261
11.
go back to reference Verdecchia A, De Angelis G, Capocaccia R (2002) Estimation and projections of cancer prevalence from cancer registry data. Stat Med 21(22):3511–3526 Verdecchia A, De Angelis G, Capocaccia R (2002) Estimation and projections of cancer prevalence from cancer registry data. Stat Med 21(22):3511–3526
12.
go back to reference Goldman AI (1984) Survivorship analysis when cure is a possibility: a Monte Carlo study. Stat Med 3(2):153–163PubMed Goldman AI (1984) Survivorship analysis when cure is a possibility: a Monte Carlo study. Stat Med 3(2):153–163PubMed
13.
go back to reference De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A (1999) Mixture models for cancer survival analysis: application to population- based data with covariates. Stat Med 18(4):441–454 De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A (1999) Mixture models for cancer survival analysis: application to population- based data with covariates. Stat Med 18(4):441–454
14.
go back to reference Mariotto A, Capocaccia R, Verdecchia A, et al. (2002) Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control 13(2):101–111PubMedCrossRef Mariotto A, Capocaccia R, Verdecchia A, et al. (2002) Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control 13(2):101–111PubMedCrossRef
15.
go back to reference Human Mortality Database. University of Californian, Berkeley (USA), and Mark Planck Institute for Demographic Research (Germany). Avaialable at http://www.mortality.org (data downloaded on August 2002) Human Mortality Database. University of Californian, Berkeley (USA), and Mark Planck Institute for Demographic Research (Germany). Avaialable at http://​www.​mortality.​org (data downloaded on August 2002)
16.
go back to reference Cronin KA, Feuer EJ (2000) Cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med 19:1729–1740PubMedCrossRef Cronin KA, Feuer EJ (2000) Cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med 19:1729–1740PubMedCrossRef
17.
go back to reference Winawer S, Fletcher R, Rex D, et al. (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124(2):544–560PubMedCrossRef Winawer S, Fletcher R, Rex D, et al. (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124(2):544–560PubMedCrossRef
Metadata
Title
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000–2020
Authors
Angela B. Mariotto
K. Robin Yabroff
Eric J. Feuer
Roberta De Angelis
Martin Brown
Publication date
01-12-2006
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 10/2006
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-006-0072-0

Other articles of this Issue 10/2006

Cancer Causes & Control 10/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine